<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852435</url>
  </required_header>
  <id_info>
    <org_study_id>NHL-001</org_study_id>
    <nct_id>NCT01852435</nct_id>
  </id_info>
  <brief_title>R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B</brief_title>
  <official_title>A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70&#xD;
      Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma&#xD;
      Grade 3B patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in&#xD;
      the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 4 cycles during treatment and then every 3 months for 2 years</time_frame>
    <description>21 days as one cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed using the CTCAE</measure>
    <time_frame>Days 1 of each course and then every 3 months for 2 years</time_frame>
    <description>21 days as one cycle</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">648</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <condition>Follicular Lymphoma Grade 3B</condition>
  <arm_group>
    <arm_group_label>R-CHOP-50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CEOP-70</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CEOP-90</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CEOP-70</intervention_name>
    <arm_group_label>R-CEOP-70</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CEOP-90</intervention_name>
    <arm_group_label>R-CEOP-90</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP-50</intervention_name>
    <arm_group_label>R-CHOP-50</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed de novo diffuse large B-cell lymphoma or follicular lymphoma&#xD;
             grade 3B&#xD;
&#xD;
          2. Age&gt;=16 y.o.,&lt;=80 y.o.&#xD;
&#xD;
          3. ECOG &lt; 3&#xD;
&#xD;
          4. No past history of malignancy&#xD;
&#xD;
          5. Radiologically measurable disease, CT imaging in screening showing 2 or more clearly&#xD;
             demarcated lesions with a largest diameter &gt; 1.5 cm, or 1 clearly demarcated lesion&#xD;
             with a largest diameter &gt; 2.0 cm.&#xD;
&#xD;
          6. Life expectancy&gt;6 months&#xD;
&#xD;
          7. Informed consented&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy before&#xD;
&#xD;
          2. Bone marrow transplantation before&#xD;
&#xD;
          3. History of malignancy&#xD;
&#xD;
          4. Active infectious disease requiring general antibiotics, anti-fungal or anti-virus&#xD;
             therapy&#xD;
&#xD;
          5. Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious&#xD;
             disease&#xD;
&#xD;
          6. Primary cutaneous, CNS, mediastinal DLBCL&#xD;
&#xD;
          7. LVEFâ‰¤50%&#xD;
&#xD;
          8. Other uncontrollable medical condition that may that may interfere the participation&#xD;
             of the study&#xD;
&#xD;
          9. Lab at enrollment(unless caused by lymphoma)&#xD;
&#xD;
               -  Neutrophile&lt;1.5*10^9/L&#xD;
&#xD;
               -  Platelet&lt;80*10^9/L&#xD;
&#xD;
               -  Hemoglobulin&lt;100g/L&#xD;
&#xD;
               -  ALT or AST &gt;2*ULN,AKP or bilirubin &gt;1.5*ULN&#xD;
&#xD;
               -  Creatinine&gt;1.5*ULN&#xD;
&#xD;
         10. Not able to comply to the protocol for mental or other unknown reasons&#xD;
&#xD;
         11. Pregnant or lactation&#xD;
&#xD;
         12. Active liver or biliary disease&#xD;
&#xD;
         13. If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If&#xD;
             HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA&#xD;
             positive patients cannot be enrolled.&#xD;
&#xD;
         14. HIV infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Zhao, MD, PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first hospital of China medical university</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial Tumor Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincal Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>diffuse large B-cell lymphoma</keyword>
  <keyword>follicular lymphoma grade 3B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

